ANDROCUR TABLET
Land: Canada
Språk: engelsk
Kilde: Health Canada
Preparatomtale
(SPC)
13-05-2021
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
CYPROTERONE ACETATE
Tilgjengelig fra:
BAYER INC
ATC-kode:
G03HA01
INN (International Name):
CYPROTERONE
Dosering :
50MG
Legemiddelform:
TABLET
Sammensetning:
CYPROTERONE ACETATE 50MG
Administreringsrute:
ORAL
Enheter i pakken:
60
Resept typen:
Prescription
Terapeutisk område:
OTHER MISCELLANEOUS THERAPEUTIC AGENTS
Produkt oppsummering:
Active ingredient group (AIG) number: 0116806001; AHFS:
Autorisasjon status:
APPROVED
Autorisasjon dato:
2007-03-21
Preparatomtale
_ANDROCUR Product Monograph_
Page 1 of 32
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ANDROCUR
®
cyproterone acetate tablets
50 mg
PR
ANDROCUR
® DEPOT
Cyproterone acetate injection
100 mg/mL
Antiandrogen
Bayer Inc.
2920 Matheson Blvd East,
Mississauga, Ontario
L4W 5R6
www.bayer.ca
Date of Initial Approval:
April 26, 1985
Date of Revision:
May 13, 2021
Submission Control No: 245903
©
2021, Bayer Inc.
® TM see www.bayer.ca/tm-mc.
_ANDROCUR Product Monograph_
Page 2 of 32
Sections or subsections that are not applicable at the time of
authorization are not listed.
TABLE OF CONTENTS ...................................................................................................................2
PART I: HEALTH PROFESSIONAL
INFORMATION...............................................................................................................
3
1.
INDICATIONS
................................................................................................................................................................
3
2.
CONTRAINDICATIONS
.................................................................................................................................................
3
3.
SERIOUS
WARNINGS
AND
PRECAUTIONS
.................................................................................................................
3
4.
DOSAGE
AND
ADMINISTRATION................................................................................................................................
3
4.1 Dosing Considerations
..........................................................................................................................................
3
4.2 Recommended Dose and Dosage
Adjustment....................................................................................................
3
4.3 Reconstitution
.......................................................................................................................................................
4
4.4 Administration
.........
Les hele dokumentet
